Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Completed · Phase 2

Conditions studied: Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma

In brief

This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Key facts

Study ID

NCT00459862

Run by

National Cancer Institute (NCI)

People needed

34

Starts

2007-03-01

Expected to finish

2013-05-01

Last updated by the study team

2015-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed malignant pleural mesothelioma:
• Measurable disease
• No progressive disease inside or outside of any prior radiation field
• No symptomatic, untreated, or uncontrolled CNS metastases
• Patients with CNS metastases treated with whole brain radiation (WBRT) may be enrolled after completion of WBRT
• Patients may begin study therapy as early as the next day after completion of WBRT
• ECOG performance status 0-2
• Life expectancy >= 12 weeks
• ANC >=1,500/mm\^3
• Platelet count >= 100,000/mm\^3
• WBC >= 3,000/mm\^3
• Bilirubin =< 1.5 times upper limit of normal (ULN)
• AST and ALT =< 2.5 times ULN
• Alkaline phosphatase =< 2.5 times ULN
• Creatinine =< 1.5 times ULN or creatinine clearance >= 50 mL/min
• Proteinuria =< 1+ on 2 consecutive dipsticks taken >= 1 week apart
• No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following:
• Gastrointestinal tract disease resulting in an inability to take oral medication
• Requirement for IV alimentation
• Prior surgical procedures affecting absorption
• Active peptic ulcer disease
• No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence
• Patients with a history of low-grade (Gleason score =< 6) localized prostate cancer are eligible even if diagnosed within the past 5 years
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study
• None of the following concurrent severe and/or uncontrolled medical conditions:

Where it is running

• North Central Cancer Treatment Group — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.